Araceli Biosciences Inc.

TIGARD, OR · Founded 2022 · Biotech · Private

Therapeutic discovery platform using advanced screening and characterization technologies

New patent ·
Claim this profile

Follows are private to you and power your alerts

Updated · aracelibio.com

Sector
Biotech
Headquarters
TIGARD, OR
Founded
2022
Latest Form D
$2.5M, Jan 2025
Total capital
$4.8M
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
$4.8M
2 Form D · last Jan 2025
21 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
20
20 pending · first 2023
Rank in peer group#13 of 342

Capital timeline

202320242025FEDERAL ↑EQUITY ↓Cumulative $4.8M1st Form D$2.2M2nd Form D$2.5M
202320242025FEDERAL ↑EQUITY ↓Cumulative $4.8M1st Form D$2.2M2nd Form D$2.5M

Latest events

  • Private capital raisedForm D · SEC · 2nd filing$2.5M
  • Private capital raisedForm D · SEC · 1st filing$2.2M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 342 peers

Line = median

Biotech · Platform

  • Granted patents#13 · top 4%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

From SEC Form D filings
  • Bruce William RhineDirectorNamed in SEC Form D filings
  • Jeff William HarrisExecutive OfficerNamed in SEC Form D filings
  • J. William FreytagDirectorNamed in SEC Form D filings
  • J. William FreytagDirectorNamed in SEC Form D filings
  • Kevin William GabeleinDirectorNamed in SEC Form D filings
  • Kirk MalloyDirectorNamed in SEC Form D filings
Show all 12 people
  • Matt BeaudetExecutive Officer, DirectorNamed in SEC Form D filings
  • Samraat RahaDirectorNamed in SEC Form D filings
  • Scott William IglExecutive OfficerNamed in SEC Form D filings
  • Sean William O'NeillDirectorNamed in SEC Form D filings
  • Shawn MacDonaldExecutive OfficerNamed in SEC Form D filings
  • William B CortelyouDirectorNamed in SEC Form D filings

What it has protected

USPTO · 20 granted of 40
Show all 40 patent records
  • AptamiR Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
  • Trethera CorpSimilar federal contract value in Biotech · null in contracts
  • Vascugen, Inc.Similar federal contract value in Biotech · null in contracts
  • Enable MedicineSimilar federal contract value in Biotech · null in contracts
  • Dimension Inx Corp.Similar federal contract value in Biotech · null in contracts
  • Scienture Inc.Similar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .